Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

November 10, 2017: By Joan McKenna

Valeant PharmaceuticalsValeant reported Nov. 7 that its Bausch + Lomb/International segment grew 1 percent (2 percent cc) in Q3-2017 year over year and accounted for nearly 57 percent of Valeant’s total revenues.

Valeant’s revenues for the quarter totaled $2.2 billion, down 10 percent year over year. Its net income was $1.3 billion compared with a net loss of $1.22 billion for the same period in 2016.

BauschThe Bausch + Lomb segment’s revenues totaled $1.25 billion in the third quarter, up from $1.24 billion in Q3-2016.

Laval, Quebec-based Valeant also reported that it reduced total debt by about $6 billion since the end of the first quarter of 2016. The company’s current long-term debt is $27.43 billion.

“Valeant is a very different company today than it was a year ago,” CEO Joseph Papa said in a statement. “Under a new management team, we have strengthened our balance sheet and stabilized the company by simplifying our business and allocating resources more efficiently.”

Within the Bausch + Lomb/International segment, the Global Surgical segment posted $161 million in revenues in Q3-2017, a 4 percent increase over Q3-2016; the Global Vision Care segment reported $208 million, a 5 percent increase; Global Consumer Products posted revenues of $392 million, a decline of 2 percent; and Global Ophthalmology Rx reported revenues of $149 million, a decline of 8 percent.

Valeant updated its guidance for 2017, expecting full-year revenues in the range of $8.65 billion to $8.80 billion, down slightly from previous guidance of $8.70 billion to $8.90 billion.

Also, Valeant reported Nov. 6 that it gave back its Sprout subsidiary, maker of the female libido product Addyi, to the former owners for a 6 percent royalty on future sales of Addyi. Valeant acquired the unit for $1 billion in 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023